Summary of evidence for role and therapeutic potential of the B7 family molecules in hematological malignancy, with citations discussed in this review
| B7 targets . | Phase 1/2 trial agent . | Preclinical evidence base . | Phase 1/2 evidence oncology . | Phase 1/2 evidence Hemato-oncology . |
|---|---|---|---|---|
| Augmentation of systemic antitumor immunity | ||||
| CTLA4 blockade | Ipilimumab | 18 | 46, 47 | 48 |
| PD-1/PD-L1 blockade | BMS936558, BMS936559, MK-3475 | 60-62 | 92-94 | 95 |
| ICOS pathway modulation | X | 169, 171 | X | X |
| Tumor-directed therapy against B7 targets | ||||
| CD80 | Galiximab | 18 | X | 42–44 |
| PD-L1 | X | 57, 61 | 92-94 | X |
| B7-H6 | X | 191, 192 | X | X |
| Augmentation of GVL | ||||
| CTLA4 blockade | Ipilimumab | 97 | 46, 47 | 96 |
| PD-1/PD-L1 blockade | X | 98 | X | X |
| ICOS pathway modulation | X | 169 | X | X |
| Attenuation of GVHD | ||||
| CTLA4 stimulation | CTLA4.Ig | 127 | X | 128, 129 |
| CD80/86 blockade | CD80/86 mAb | 127 | X | X |
| ICOS pathway modulation | X | 173, 174 | X | X |
| Bioengineered T cells | ||||
| CD28 CAR | Modified T cell | 123 | X | 125, 126 |
| CD80 CAR | Modified T cell | 124 | X | X |
| NKp30 CAR | Modified NK cell | 191 | X | X |
| Antitumor vaccine augmentation | ||||
| CTLA4 blockade | Ipilimumab | 18 | 110 | 48 111 |
| PD-1/PD-L1 blockade | X | 112, 113 | X | X |
| Treg depletion and inactivation | ||||
| CTLA-4 blockade | X | 136, 137 | X | X |
| B7 targets . | Phase 1/2 trial agent . | Preclinical evidence base . | Phase 1/2 evidence oncology . | Phase 1/2 evidence Hemato-oncology . |
|---|---|---|---|---|
| Augmentation of systemic antitumor immunity | ||||
| CTLA4 blockade | Ipilimumab | 18 | 46, 47 | 48 |
| PD-1/PD-L1 blockade | BMS936558, BMS936559, MK-3475 | 60-62 | 92-94 | 95 |
| ICOS pathway modulation | X | 169, 171 | X | X |
| Tumor-directed therapy against B7 targets | ||||
| CD80 | Galiximab | 18 | X | 42–44 |
| PD-L1 | X | 57, 61 | 92-94 | X |
| B7-H6 | X | 191, 192 | X | X |
| Augmentation of GVL | ||||
| CTLA4 blockade | Ipilimumab | 97 | 46, 47 | 96 |
| PD-1/PD-L1 blockade | X | 98 | X | X |
| ICOS pathway modulation | X | 169 | X | X |
| Attenuation of GVHD | ||||
| CTLA4 stimulation | CTLA4.Ig | 127 | X | 128, 129 |
| CD80/86 blockade | CD80/86 mAb | 127 | X | X |
| ICOS pathway modulation | X | 173, 174 | X | X |
| Bioengineered T cells | ||||
| CD28 CAR | Modified T cell | 123 | X | 125, 126 |
| CD80 CAR | Modified T cell | 124 | X | X |
| NKp30 CAR | Modified NK cell | 191 | X | X |
| Antitumor vaccine augmentation | ||||
| CTLA4 blockade | Ipilimumab | 18 | 110 | 48 111 |
| PD-1/PD-L1 blockade | X | 112, 113 | X | X |
| Treg depletion and inactivation | ||||
| CTLA-4 blockade | X | 136, 137 | X | X |
mAb indicates monoclonal antibody; NK, natural killer; CTLA, cytolytic T cell–associated sequence-4; PD, programmed cell death; ICOS, inducible costimulator; CAR, chimeric antigen receptor; and X, there are currently no data or therapeutic agent available.